Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients
2022-001514-18Phase 2Active
- Sponsor
- University Medical Centre Ljubljana
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of letermovir in cytomegalovirus disease (CMV) (2 arms), sponsored by University Medical Centre Ljubljana. Primary endpoint: Rate of early CMV infections/disease during virostatic prophylaxis. Started May 2022; status: active.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2022-001514-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001514-18.